Cancer Family
Malignant Neoplasm
CI-CAN-00000025CAExplore in graph →
20,108 active trials259 approved drugs3,741 evidence items
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000025CAExplore in graph →
Clinical trials
90,662 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (11,158)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04547062 | Monocentric Phase 1 Study With Escalation of Doses of Tocilizumab in Combination With Chemotherapy (Idarubicin and Cytarabine) in Patients With Acute Myeloblastic Leukemia (AML)(Tocilam) | completed | Phase 1 | 12 | Nantes University HospitalOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04921904 | Abemaciclib Plus Ramucirumab for Esophageal/Gastroesophageal Junction Ca | completed | Phase 1 / Phase 2 | 26 | Baylor Research InstituteOTHER | 1 | Sep 14, 2026 |
| clinicaltrials |
| NCT05858736 | Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors(PRESERVE-009) | completed | Phase 1 | 18 | OncoC4, Inc.INDUSTRY | 1 | Sep 14, 2026 | clinicaltrials |
| NCT05882734 | Tuvusertib (M1774) in Combination With Cemiplimab in Participants With Non-Squamous NSCLC (DDRiver NSCLC 322) | completed | Phase 1 / Phase 2 | 61 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT05821231 | Study Evaluating the Safety and Efficacy of MEDI5752 in Combination With Stereotactic Radiotherapy in Patients With Metastatic Sarcoma(MEDISARC-SBRT) | completed | Phase 1 | 14 | Institut Claudius RegaudOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT05027386 | Apatinib Mesylate Combined With IT Regimen for the Treatment of Recurrent or Refractory Neuroblastoma: A Single-arm, Phase I/II，Multi-center, Clinical Study. | completed | Phase 1 / Phase 2 | 125 | Sun Yat-sen UniversityOTHER | 1 | Sep 10, 2026 | clinicaltrials |
| NCT04104672 | A Study to Evaluate the Safety and Tolerability of AB680 in Participants With Gastrointestinal Malignancies(ARC-8) | completed | Phase 1 | 196 | Arcus Biosciences, Inc.INDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT05320809 | Study of 3D189 in Patients With Hematologic Malignancies | completed | Phase 1 | 16 | 3D MedicinesINDUSTRY | 1 | Sep 9, 2026 | clinicaltrials |
| NCT04997902 | Combination Trial of Tipifarnib and Alpelisib in Adult Recurrent/ Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) | completed | Phase 1 / Phase 2 | 45 | Kura Oncology, Inc.INDUSTRY | 1 | Sep 8, 2026 | clinicaltrials |
| NCT06167486 | SG2918 For Advanced Malignant Tumors | completed | Phase 1 | 17 | Hangzhou Sumgen Biotech Co., Ltd.INDUSTRY | 1 | Sep 4, 2026 | clinicaltrials |
| NCT03657576 | Trial of C134 in Patients With Recurrent GBM(C134-HSV-1) | completed | Phase 1 | 19 | University of Alabama at BirminghamOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03674567 | Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab | completed | Phase 1 / Phase 2 | 323 | RAPT Therapeutics, Inc.INDUSTRY | 6 | Sep 3, 2026 | clinicaltrials |
| NCT05282459 | Enasidenib in MDS &Non-proliferative Chronic Myelomonocytic Leukemia w/o IDH2 Mutation | completed | Phase 1 / Phase 2 | 17 | Tian Yi ZhangOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT07802977 | Intraparenchymal Salivary Gland Corticosteroid Injection to Prevent Radiation-Induced Xerostomia | completed | Phase 1 | 10 | University of California, DavisOTHER | 1 | Sep 3, 2026 | clinicaltrials |
| NCT03502785 | INO-5401 + INO-9012 in Combination With Atezolizumab in Locally Advanced Unresectable or Metastatic/Recurrent Urothelial Carcinoma | completed | Phase 1 / Phase 2 | 35 | Inovio PharmaceuticalsINDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT04276493 | Anti-HER2 Bispecific Antibody Zanidatamab (ZW25) Activity in Combination With Chemotherapy With/Without Tislelizumab | completed | Phase 1 / Phase 2 | 71 | BeiGeneINDUSTRY | 3 | Sep 2, 2026 | clinicaltrials |
| NCT04330820 | Trial for Relapsed or Refractory AML Patients Combining Cytarabine and Mitoxantrone With Venetoclax (RELAX)(RELAX) | completed | Phase 1 / Phase 2 | 55 | Technische Universität DresdenOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05721846 | Nivolumab With Ipilimumab Combined With TGFβ-15 Peptide Vaccine and Radiotherapy for Pancreatic Cancer(CheckVAC) | completed | Phase 1 | 20 | Inna Chen, MDOTHER | 1 | Sep 2, 2026 | clinicaltrials |
| NCT05864144 | A Study of SNS-101 (Anti VISTA) Monotherapy and in Combination With Cemiplimab in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 98 | Sensei Biotherapeutics, Inc.INDUSTRY | 1 | Sep 2, 2026 | clinicaltrials |
| NCT01333046 | Administration of TAA-Specific CTLs; Hodgkin or Non-Hodgkin Lymphoma; TACTAL(TACTAL) | completed | Phase 1 | 36 | Baylor College of MedicineOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT01875601 | NK White Blood Cells and Interleukin in Children and Young Adults With Advanced Solid Tumors | completed | Phase 1 | 16 | National Cancer Institute (NCI)NIH | 1 | Sep 1, 2026 | clinicaltrials |
| NCT03021460 | Pembrolizumab and Ibrutinib in Treating Patients With Stage III-IV Melanoma That Cannot Be Removed by Surgery | completed | Phase 1 | 20 | Mayo ClinicOTHER | 1 | Sep 1, 2026 | clinicaltrials |
| NCT04305041 | Substudy 02A: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents in Participants With Programmed Cell-death 1 (PD-1) Refractory Melanoma (MK-3475-02A/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 100 | Merck Sharp & Dohme LLCINDUSTRY | 7 | Sep 1, 2026 | clinicaltrials |
| NCT04201873 | Pembrolizumab and a Vaccine (ATL-DC) for the Treatment of Surgically Accessible Recurrent Glioblastoma | completed | Phase 1 | 46 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Aug 31, 2026 | clinicaltrials |
| NCT01582191 | Vandetanib and Everolimus in Treating Patients With Advanced or Metastatic Cancer | completed | Phase 1 | 123 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03388619 | Highly Conformal, Hypofractionated, Focally Dose Escalated Post-Prostatectomy Radiotherapy | completed | Phase 1 | 30 | National Cancer Institute (NCI)NIH | 1 | Aug 28, 2026 | clinicaltrials |
| NCT03131908 | Study of the Selective PI3K-Beta Inhibitor GSK2636771 in Combination With Pembrolizumab in Patients With Metastatic Melanoma and PTEN Loss | completed | Phase 1 / Phase 2 | 28 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT03674073 | A Study Combining Personalized Neoantigen-based Dendritic Cell Vaccine With Microwave Ablation for the Treatment of Hepatocellular Carcinoma | completed | Phase 1 | 24 | Chinese PLA General HospitalOTHER | 1 | Aug 27, 2026 | clinicaltrials |
| NCT04303169 | Substudy 02C: Safety and Efficacy of Pembrolizumab in Combination With Investigational Agents or Pembrolizumab Alone in Participants With Stage III Melanoma Who Are Candidates for Neoadjuvant Therapy (MK-3475-02C/KEYMAKER-U02) | completed | Phase 1 / Phase 2 | 146 | Merck Sharp & Dohme LLCINDUSTRY | 6 | Aug 27, 2026 | clinicaltrials |
| NCT02494167 | Administration of Donor Multi TAA-Specific T Cells for AML or MDS (ADSPAM) | completed | Phase 1 | 30 | Baylor College of MedicineOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT04209595 | PLX038 (PEGylated SN38) and Rucaparib in Solid Tumors and Small Cell Cancers | completed | Phase 1 / Phase 2 | 10 | National Cancer Institute (NCI)NIH | 1 | Aug 26, 2026 | clinicaltrials |
| NCT06863233 | A Study of CD8+ T Cell Imaging During Treatment in People With Non-Small Cell Lung Cancer | completed | Phase 1 | 4 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Aug 26, 2026 | clinicaltrials |
| NCT05241834 | A Study of LOXO-260 in Cancer Patients With a Change in a Particular Gene (RET) That Has Not Responded to Treatment | completed | Phase 1 | 70 | Eli Lilly and CompanyINDUSTRY | 2 | Aug 21, 2026 | clinicaltrials |
| NCT05395741 | Regorafenib in Patients With Refractory Primary Bone Tumors(Regbone) | completed | Phase 1 / Phase 2 | 30 | Institute of Mother and Child, Warsaw, PolandOTHER | 1 | Aug 21, 2026 | clinicaltrials |
| NCT04902872 | Study of CBX-12 in Subjects With Advanced or Metastatic Refractory Solid Tumors | completed | Phase 1 / Phase 2 | 69 | Cybrexa TherapeuticsINDUSTRY | 1 | Aug 20, 2026 | clinicaltrials |
| NCT00412503 | Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents | completed | Phase 1 | — | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT01791478 | BYL719 and Letrozole in Post-Menopausal Patients With Hormone Receptor-Positive Metastatic Breast Cancer | completed | Phase 1 | 46 | Vanderbilt-Ingram Cancer CenterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT02223208 | Ro Plus CHOEP as First Line Treatment Before HSCT in Young Patients With Nodal Peripheral T-cell Lymphomas(FIL_PTCL13) | completed | Phase 1 / Phase 2 | 89 | Fondazione Italiana Linfomi - ETSOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05036577 | A Dose-escalating Pilot Study of Orelabrutinib for Newly-diagnosed PCNSL(ORMD2021) | completed | Phase 1 | 13 | Huashan HospitalOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05046171 | Decreasing Polypharmacy in Older Adults With Curable Cancers Trial | completed | Phase 1 / Phase 2 | 50 | University of RochesterOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT05220046 | Palliadelic Treatment to Reduce Psychological Distress in Persons With Advanced Gastrointestinal Cancers | completed | Phase 1 | 18 | University of NebraskaOTHER | 1 | Aug 19, 2026 | clinicaltrials |
| NCT03096054 | A Phase I Trial of LY3143921 Hydrate in Solid Tumours | completed | Phase 1 | 69 | Cancer Research UKOTHER | 1 | Aug 18, 2026 | clinicaltrials |
| NCT04432597 | HPV Vaccine PRGN-2009 Alone or in Combination With Anti-PDL1/TGF-Beta Trap (M7824) in Subjects With HPV Associated Cancers | completed | Phase 1 / Phase 2 | 39 | National Cancer Institute (NCI)NIH | 1 | Aug 18, 2026 | clinicaltrials |
| NCT06047184 | Phase I Study of BEBT-209 in Women With Advanced Breast Cancer | completed | Phase 1 | 100 | BeBetter Med IncINDUSTRY | 1 | Aug 18, 2026 | clinicaltrials |
| NCT00720785 | Natural Killer Cells and Bortezomib to Treat Cancer | completed | Phase 1 | 35 | National Heart, Lung, and Blood Institute (NHLBI)NIH | 1 | Aug 17, 2026 | clinicaltrials |
| NCT01167530 | Study to Evaluate RAD001 in Combination With Radiotherapy in Non-small Cell Lung Cancer(RAD001) | completed | Phase 1 | 26 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03650764 | Ramucirumab + Pembrolizumab in Patients With Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma | completed | Phase 1 / Phase 2 | 43 | Washington University School of MedicineOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT04370704 | Study of Combination Therapy With INCMGA00012 (Anti-PD-1), INCAGN02385 (Anti-LAG-3), and INCAGN02390 (Anti-TIM-3) in Participants With Select Advanced Malignancies | completed | Phase 1 / Phase 2 | 61 | Incyte CorporationINDUSTRY | 2 | Aug 17, 2026 | clinicaltrials |
| NCT04942626 | Capecitabine-based Chemoradiotherapy in Combination With the IL-1 Receptor Antagonist Anakinra for Rectal Cancer Patients(ACO/ARO/AIO-21) | completed | Phase 1 | 12 | Goethe UniversityOTHER | 1 | Aug 17, 2026 | clinicaltrials |
| NCT03283605 | Immunotherapy and SBRT for Metastatic Head and Neck Carcinomas | completed | Phase 1 / Phase 2 | 33 | Centre hospitalier de l'Université de Montréal (CHUM)OTHER | 1 | Aug 14, 2026 | clinicaltrials |
Data updated 16 days agoSource updated Sep 14, 2026source: clinicaltrials